# Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

> **NCT02575963** · PHASE1,PHASE2 · COMPLETED · sponsor: **Actinium Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- AML

## Interventions

- **DRUG:** Cytarabine (Phase 1 only)
- **BIOLOGICAL:** Lintuzumab-Ac225
- **DRUG:** Furosemide (Phase 1 only)
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT02575963
- **Lead sponsor:** Actinium Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2018-11
- **Final completion:** 2020-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02575963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02575963, "Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02575963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*